^
    CANCER:
    Hepatocellular Cancer
    ASS1 negative
    HCC
    BCT-100
    Sensitive
    :
    C3
    Invest New Drugs - 3wk
    No biomarker
    HCC
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    HCC
    bevacizumab + atezolizumab
    Sensitive
    :
    A1
    No biomarker
    HCC
    cabozantinib tablet
    Sensitive
    :
    A1
    No biomarker
    HCC
    nivolumab
    Sensitive
    :
    A1
    AFP elevation
    HCC
    ramucirumab
    Sensitive
    :
    A1
    No biomarker
    HCC
    regorafenib
    Sensitive
    :
    A1
    No biomarker
    HCC
    lenvatinib
    Sensitive
    :
    A1
    No biomarker
    HCC
    sorafenib
    Sensitive
    :
    A1
    No biomarker
    HCC
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    NTRK3 fusion
    HCC
    larotrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    HCC
    larotrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    HCC
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    HCC
    entrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    HCC
    entrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    HCC
    entrectinib
    Sensitive
    :
    A2
    No biomarker
    HCC
    sirolimus
    Sensitive
    :
    A2
    No biomarker
    HCC
    sintilimab + Byvasda (bevacizumab biosimilar)
    Sensitive
    :
    B
    AFP elevation
    HCC
    regorafenib
    Sensitive
    :
    B
    FGF21-H
    HCC
    lenvatinib
    Sensitive
    :
    B
    No biomarker
    HCC
    SRF388
    Sensitive
    :
    B
    HGF-H + VEGFA-H
    HCC
    erlotinib + sorafenib
    Resistant
    :
    B
    AFP elevation
    HCC
    sorafenib + LY2157299
    Sensitive
    :
    C2
    TSC2 overexpression
    HCC
    everolimus
    Resistant
    :
    C3
    FOXA3 overexpression
    HCC
    sorafenib
    Sensitive
    :
    C3
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES